Belite Bio (BLTE) director Lu Ita reports 110,000-share option stake

Rhea-AI Filing Summary

BELITE BIO, INC director Lu Ita filed an initial Form 3 showing existing stock option holdings. The filing reports a stock option over 50,000 ordinary shares with a $14.45 exercise price, expiring on July 16, 2033. This option vests 22,500 shares on July 17, 2023, with the remaining 27,500 shares vesting in 22 equal monthly installments following June 28, 2023, subject to continued service.

The filing also reports a second stock option over 60,000 ordinary shares with a $58.88 exercise price, expiring on April 14, 2035. This option vests in 36 equal monthly installments for each full month of services completed following April 15, 2025, also subject to continued service. The document records holdings only and does not show any new purchases or sales.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lu Ita

(Last) (First) (Middle)

5F-7 NO. 1 SECTION 2 XIN-YI ROAD

(Street)

TAIPEI TAIWAN 100

(City) (State) (Zip)

TAIWAN, PROVINCE OF CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	07/16/2033	Ordinary Shares	50,000	$14.45	D
Stock Option (right to buy)	(2)	04/14/2035	Ordinary Shares	60,000	$58.88	D

Explanation of Responses:

1. The option shall vest (i) as to 22,500 ordinary shares on July 17, 2023, and (ii) as to the remaining 27,500 ordinary shares subject to the option in 22 equal and continuous monthly installments for each full month of services completed following June 28, 2023, subject to continued service to the Issuer on each such date.

2. The option shall vest as to 60,000 ordinary shares subject to the option in 36 equal and continue monthly installments for each full month of services completed following April 15, 2025, subject to continued service to the Issuer on such date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Ita Lu	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Belite Bio (BLTE) director Lu Ita report on this Form 3?

The Form 3 shows existing stock option holdings for director Lu Ita in Belite Bio. It lists two stock option awards over 50,000 and 60,000 ordinary shares, including their exercise prices, expiration dates, and detailed vesting schedules tied to continued service.

How many Belite Bio (BLTE) shares are covered by Lu Ita’s reported options?

The filing reports stock options over 110,000 ordinary shares in total. One option covers 50,000 shares at a $14.45 exercise price, and another covers 60,000 shares at a $58.88 exercise price, both subject to specified vesting conditions and expiration dates.

What are the vesting terms of Lu Ita’s 50,000-share option in Belite Bio (BLTE)?

The 50,000-share option vests 22,500 shares on July 17, 2023, with the remaining 27,500 shares vesting in 22 equal monthly installments after June 28, 2023. Vesting is conditioned on Lu Ita’s continued service to Belite Bio on each applicable vesting date.

When do Lu Ita’s Belite Bio (BLTE) stock options expire?

The Form 3 states that one option over 50,000 shares expires on July 16, 2033, and the second option over 60,000 shares expires on April 14, 2035. These expiration dates define the latest time by which the options may be exercised, assuming vesting and continued service.

Does this Belite Bio (BLTE) Form 3 show any insider buying or selling?

No, this Form 3 does not show new purchases or sales of Belite Bio shares. It is an initial ownership report listing Lu Ita’s existing stock option awards and their vesting and expiration terms, rather than documenting open-market trades or option exercises.